Marinomed Biotech AG

MARI.VI · VIE
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Market Cap€26,675€44,331€84,538€129,875
- Cash€1,706€2,589€8,175€5,802
+ Debt€29,504€21,797€22,628€15,798
Enterprise Value€54,472€63,540€98,990€139,871
Revenue€4,747€9,184€11,276€11,628
% Growth-48.3%-18.6%-3%
Gross Profit-€4,268€1,143€2,141€1,424
% Margin-89.9%12.4%19%12.2%
EBITDA-€7,181-€3,623-€3,213-€3,576
% Margin-151.3%-39.4%-28.5%-30.8%
Net Income-€15,416-€6,795-€6,398-€5,891
% Margin-324.8%-74%-56.7%-50.7%
EPS Diluted-8.67-4.5-4.27-3.99
% Growth-92.7%-5.4%-7%
Operating Cash Flow-€4,528-€5,203-€4,866
Capital Expenditures-€129-€228-€919
Free Cash Flow-€4,657-€5,431-€5,785
Marinomed Biotech AG (MARI.VI) Financial Statements & Key Stats | AlphaPilot